Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all The following terms were not found in PubMed: NCT02320149, NCT02322866
Page 1
Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris.
Moore AY, Charles JEM, Moore S. Moore AY, et al. Future Microbiol. 2019 Sep;14(14):1235-1242. doi: 10.2217/fmb-2019-0199. Epub 2019 Sep 2. Future Microbiol. 2019. PMID: 31475868 Free PMC article. Review.
Unlike many acne studies, sarecycline was investigated for chest and back acne. Significant reduction in inflammatory lesions was seen at week 12 at 1.5 mg/kg/day of sarecycline, with statistically significant improvement seen as early as week 3. No reports o …
Unlike many acne studies, sarecycline was investigated for chest and back acne. Significant reduction in inflammatory lesions was see …
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Moore A, et al. J Drugs Dermatol. 2018 Sep 1;17(9):987-996. J Drugs Dermatol. 2018. PMID: 30235387 Clinical Trial.
METHODS: Patients 9-45 years with moderate to severe facial acne (Investigator's Global Assessment [IGA] score 3, 20-50 inflammatory and 100 noninflammatory lesions, and 2 nodules) were randomized 1:1 to sarecycline 1.5 mg/kg/day or placebo for 12 weeks in identical …
METHODS: Patients 9-45 years with moderate to severe facial acne (Investigator's Global Assessment [IGA] score 3, 20-50 inflammatory …
Sarecycline Review.
Haidari W, Bruinsma R, Cardenas-de la Garza JA, Feldman SR. Haidari W, et al. Ann Pharmacother. 2020 Feb;54(2):164-170. doi: 10.1177/1060028019873111. Epub 2019 Aug 28. Ann Pharmacother. 2020. PMID: 31462063 Review.

Data Synthesis: In a phase 3 clinical trial (SC1401), absolute change from baseline in facial inflammatory lesion count at week 12 was -15.3 for the sarecycline arm and -10.1 for placebo (P < 0.01). In another phase 3 clinica

Data Synthesis: In a phase 3 clinical trial (SC1401), absolute change from baseline in facial inflammatory lesion count …